MedTrace Logo

Enteropathy and Diabetes in HIV Patients

NCT03713502 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1947

Last updated 2021-06-29

No results posted yet for this study

Summary

Emerging data suggest that HIV-infected people have disproportionately higher risk of diabetes than HIV-uninfected people. Multiple factors may contribute to elevated diabetes risk including increased prevalence of conventional non-communicable diseases (NCDs) risk factors, use of some antiretroviral drugs regimens, and inflammation and immune activation secondary to environmental- and HIV-enteropathy. To date, enteropathy has been little studied in relation to HIV and diabetes in Sub-Saharan Africa. Enteropathy leads to systemic inflammation which may in turn result in insulin resistance and may reduce secretion of incretins, the gut hormones which stimulate synthesis and secretion of insulin. Both mechanisms could potentially result in higher diabetes risk in HIV patients. This study investigates the hypothesis that among HIV-infected patients environmental enteropathy increase the risk of diabetes. The findings of this study will provide information which could be used as a basis for developing clinical trials to address different aspects of environmental enteropathy in order to reduce the burden of diabetes among HIV-infected populations

Conditions

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • London School of Hygiene and Tropical Medicine

    collaborator OTHER

  • Queen Mary University of London

    collaborator OTHER

  • National Institute for Medical Research, Tanzania

    lead OTHER_GOV

Principal Investigators

  • Dr George PrayGod, MD, PhD · National Institute for Medical Research

  • Dr Daniel Faurholt-Jepsen, MD, PhD · University of Copenhagen

  • Prof Suzanne Filteau, PhD · London School of Hygiene and Tropical Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • Tanzania

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03713502 on ClinicalTrials.gov